RAVER1 is a dual-compartment ribonucleoprotein that functions as a critical co-factor in regulated alternative splicing, primarily through cooperation with PTBP1 1. The protein contains three RNA recognition motifs and four PTB-Raver1 interacting domains (PRIs) that bind specifically to PTBP1's second RNA recognition motif, enabling modulation of splicing events such as exon skipping and mutual exon switching in genes like TPM1 2. Beyond splicing regulation, RAVER1 serves as a scaffold protein at focal adhesions and microfilament attachment sites, where it interacts with vinculin and directs mRNA cargo to sites of local protein synthesis 3. In cancer cells, RAVER1 promotes proliferation and restricts apoptosis by controlling alternative splicing within the miR/RISC pathway, particularly modulating GW-enriched motifs in TNRC6 proteins essential for AGO2-binding and miR/RISC complex formation, thereby preventing lethal TGFB-driven epithelial-mesenchymal transition 4. RAVER1 dysregulation has emerged as clinically relevant in craniopharyngiomas, where loss of RAVER1 expression is associated with oncogenic processes and represents a potential therapeutic target 5. Additionally, RAVER1 variants identified in COVID-19 GWAS studies influence antiviral immunity through the MDA5/RAVER1 pathway, affecting ICAM1 expression and disease severity 6.